WuXi AppTec

Global Platform
One Vision

Our Vision

Every Drug Can Be Made
and Every Disease Can Be Treated

By Building an Open-access Platform with the Most Comprehensive Capabilities and Technologies in the Global Healthcare Industry

Our Values

Integrity & Dedication, Working Together & Sharing Success;
Doing the Right Thing, Doing It Right.

Stay up-to-date on industry information on COVID-19

About Us

Enabling Innovation

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,600 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

Services and Solutions

An Open Enabling Platform

Enabling more than 5,600 Innovative Collaborators from more than 30 Countries

icon

Small Molecule Drug R&D and Manufacturing

icon

Cell Therapy
and Gene Therapy

icon

Drug R&D and Medical
Device Testing

icon

Clinical
Services

icon

Small Molecule Drug R&D and Manufacturing

Company Platform

Enabling Anyone, Any Company

To Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare Industry

Research Service Division

Providing comprehensive
end-to-end drug discovery solutions

Laboratory Testing Division

Providing integrated testing solutions for drug development and medical device innovation

STA Pharmaceutical

Global leading platform for pharmaceutical development and manufacturing

Advanced Therapies Unit

Cell therapy and gene therapy R&D and production platform

WuXi Clinical

Providing global clinical development solutions, with dedicated resources in 60+ countries

WuXi SMO

Clinical trial site operation for Phase I-IV pharmaceutical and medical device study

LabNetwork

Global e-commerce platform linking R&D products, suppliers and buyers

News

The Latest News about WuXi AppTec

WuXi ATU Opens New Facility in Philadelphia, Tripling Testing Capacity to Support Global Customers

WuXi AppTec Reports Strong Third-Quarter 2021 Results

WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers

WuXi AppTec Receives AA ESG Rating from MSCI

WuXi AppTec Reports Strong 2021 Interim Results

WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

Careers

Welcome to

Our Team

Become Part of Creating a Better Life

Investors

The Latest Financial Reports, Announcements and Resources